Compare MSC & BWAY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MSC | BWAY |
|---|---|---|
| Founded | 2000 | 2003 |
| Country | Hong Kong | Israel |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 562.4M | 450.8M |
| IPO Year | 2017 | N/A |
| Metric | MSC | BWAY |
|---|---|---|
| Price | $2.87 | $13.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.25 |
| AVG Volume (30 Days) | 1.7K | ★ 132.1K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $24.33 |
| P/E Ratio | ★ N/A | $81.98 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.55 | $7.84 |
| 52 Week High | $6.63 | $26.63 |
| Indicator | MSC | BWAY |
|---|---|---|
| Relative Strength Index (RSI) | 43.62 | 29.39 |
| Support Level | $2.81 | $11.55 |
| Resistance Level | $3.28 | $17.20 |
| Average True Range (ATR) | 0.13 | 1.05 |
| MACD | 0.00 | -0.64 |
| Stochastic Oscillator | 11.86 | 14.18 |
Studio City International Holdings Ltd is a gaming, retail, and entertainment resort located in Cotai, Macau. It operates Studio City Casino with around 250 mass-market gaming tables; including tables for VIP rolling chip operations, and 552 gaming machines. Studio City features luxury hotel rooms, diverse food and beverage establishments, and complementary retail space. In addition, the company offers non-gaming attractions, including the world's first figure-8 Ferris wheel, a deluxe nightclub and karaoke venue, a live performance arena, an outdoor and an indoor water park. Geographically, the company derives the majority of its revenue from the Macau region.
BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder, and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.